CHF6001 II: A novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration - In vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 568-578

  Villetti, Gino ^a   Carnini, Chiara ^a   Battipaglia, Loredana ^a   Preynat, Laurent ^a   Bolzoni, Pier Tonino ^a   Bassani, Franco ^a   Caruso, Paola ^a   Bergamaschi, Marco ^a   Pisano, Anna Rita ^a   Puviani, Veronica ^a   Stellari, Fabio Franco ^a   Cenacchi, Valentina ^a   Volta, Roberta ^a   Bertacche, Vittorio ^a   Mileo, Valentina ^a   Bagnacani, Valentina ^a   Moretti, Elisa ^a   Puccini, Paola ^a   Catinella, Silvia ^a   Facchinetti, Fabrizio ^a   Sala, Angelo ^b,c   Civelli, Maurizio ^a   more..

^a CHIESI FARMACEUTICI S P A   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DICHLORO 4 [2 [3 (CYCLOPROPYLMETHOXY) 4 (DIFLUOROMETHOXY)PHENYL] 2 [3 (CYCLOPROPYLMETHOXY) 4(METHYLSULFONAMIDO)BENZOYLOXY]ETHYL]PYRIDINE 1 OXIDE; ANTIINFLAMMATORY AGENT; BUDESONIDE; FLUTICASONE FUROATE; GSK 256066; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; UNCLASSIFIED DRUG; 3,5-DICHLORO-4-(2-(3-(CYCLOPROPYLMETHOXY)-4-(DIFLUOROMETHOXY)PHENYL)-2-(3-(CYCLOPROPYLMETHOXY)-4-(METHYLSULFONAMIDO)BENZOYLOXY)ETHYL)PYRIDINE 1-OXIDE; 4 AMINOBENZOIC ACID DERIVATIVE; SULFONAMIDE;

ADULT; ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EOSINOPHILIA; FERRET; IN VIVO STUDY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NAUSEA; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; RAT; SINGLE DRUG DOSE; TOBACCO; TOXICITY TESTING; VOMITING; ANIMAL; BROWN NORWAY RAT; C57BL MOUSE; CHEMISTRY; DRUG SCREENING; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES; TOPICAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG EVALUATION, PRECLINICAL; FERRETS; MALE; MICE; MICE, INBRED C57BL; PARA-AMINOBENZOATES; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, INBRED BN; RATS, WISTAR; SULFONAMIDES;

EID: 84922041417     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220558     Document Type: Article

References (40)

1. Armani E, Amari G, Rizzi A, De Fanti R, Ghidini E, Capaldi C, Carzaniga L, Caruso P, Guala M, Peretto I, et al. (2014) Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem 57:793-816.
2. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, and Torphy TJ (1996) Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem Pharmacol 51:949-956.
3. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
4. Beghè B, Rabe KF, and Fabbri LM (2013) Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 188:271-278.
5. Bellofiore S and Martin JG (1988) Antigen challenge of sensitized rats increases airway responsiveness to methacholine. J Appl Physiol (1985) 65:1642-1646.
6. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290.
7. Celly CS, House A, Sehring SJ, Zhang XY, Jones H, Hey JA, Egan RW, and Chapman RW (2006) Temporal profile of forced expiratory lung function in allergen-challenged Brown-Norway rats. Eur J Pharmacol 540:147-154.
8. Daguès N, Pawlowski V, Sobry C, Hanton G, Borde F, Soler S, Freslon JL, and Chevalier S (2007) Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol Sci 100:238-247.
9. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, et al. (1996) Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125.
10. Eltom S, Stevenson C, and Birrell MA (2013) Cigarette smoke exposure as a model of inflammation associated with COPD. Curr Protoc Pharmacol 5:Unit5.64.
11. Elwood W, Lötvall JO, Barnes PJ, and Chung KF (1991) Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized brown-Norway rats. J Allergy Clin Immunol 88:951-960.
12. Esposito E, Mariotti F, Acerbi D, Compagnoni A, and Nandeuil M-A (2013) Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers. Eur Respir J 42(Suppl 57):P736.
13. Fan Chung K (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533:110-117.
14. Giembycz MA (2000) Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59:193-212.
15. Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155:288-290.
16. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
17. Kubo S, Kobayashi M, Iwata M, Takahashi K, Miyata K, and Shimizu Y (2011) Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs. Eur J Pharmacol 659:79-84.
18. Kuss H, Hoefgen N, Johanssen S, Kronbach T, and Rundfeldt C (2003) In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 307:373-385.
19. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, and Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35.
20. Martorana PA, Beume R, Lucattelli M, Wollin L, and Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848-853.
21. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A, et al. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 54:7797-7814.
22. Miller LM, Foster WM, Dambach DM, Doebler D, McKinnon M, Killar L, and Longphre M (2002) A murine model of cigarette smoke-induced pulmonary inflammation using intranasally administered smoke-conditioned medium. Exp Lung Res 28:435-455.
23. Moretto N, Caruso P, Bosco R, Marchini G, Pastore F, Armani E, Amari G, Rizzi A, Ghidini E, De Fanti R, et al. (2015) CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther 352:559-567.
24. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, and Knowles RG (2011) In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 337:137-144.
25. Okuda S, Honda M, Ito Y, Aihara E, Kato S, Mitsufuji S, Yoshikawa T, and Takeuchi K (2009) Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. J Physiol Pharmacol 60 (Suppl 7):183-190.
26. Renzi PM, Olivenstein R, and Martin JG (1993) Inflammatory cell populations in the airways and parenchyma after antigen challenge in the rat. Am Rev Respir Dis 147:967-974.
27. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, and Chan CC (2002a) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113-118.
28. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, and Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262-269.
29. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, and Chan CC (2002b) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:1045-1052.
30. Robichaud A, Tattersall FD, Choudhury I, and Rodger IW (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38:289-297.
31. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, et al. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 36:14250-14261.
32. Singh D, Leaker BR, Boyce M, Nandeuil MA, Collarini S, Mariotti F, Santoro D, and Barnes PJ (2014) The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatic subjects (Abstract). Am J Respir Crit Care Med 189:A4175.
33. Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63:2575-2594.
34. Stockley RA (2002) Neutrophils and the pathogenesis of COPD. Chest 121(5, Suppl) 151S-155S.
35. Teixeira MM, Gristwood RW, Cooper N, and Hellewell PG (1997) Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18:164-171.
36. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157:351-370.
37. Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, et al. (2011) GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther 337:145-154.
38. Wan WY, Morris A, Kinnear G, Pearce W, Mok J, Wyss D, and Stevenson CS (2010) Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation. Respir Res 11:126.
39. Watz H, Mistry SJ, and Lazaar AL; IPC101939 investigators (2013) Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther 26:588-595.
40. Wright JL and Churg A (2002) A model of tobacco smoke-induced airflow obstruction in the guinea pig. Chest 121(5, Suppl)188S-191S.